CD33 and neoplasm: This initial clinical work indicates that CD33-CAR-NK therapy may offer a new therapeutic option for R/R AML, which aims to reduce the tumor burden, eliminate LSCs, and provide opportunity to combine it with other therapies for more effective treatment of the R/R AML patients.